[Clinical effect of combination chemotherapy with peplomycin and mitomycin C (PM therapy) in recurrent uterine cervical cancer].

Abstract

Seventeen patients with recurrent uterine cervical cancer were treated with combination chemotherapy consisting of consecutive intravenous drip infusion of PEP 5 mg for 6 days and intravenous infusion of MMC 10 mg on the 6th day. Of twelve evaluable cases, 2 complete responses and 6 partial responses were obtained and the response rate was 67%. The median survival for responders was 61.3 weeks as compared with 28.0 weeks for non-responders. The initial clinical effect appeared after at least two courses. Pulmonary toxicity in the form of interstitial pneumonitis occurred in 8 cases (50%) including 2 cases of pulmonary fibrosis. This result suggests that PM therapy is a very useful treatment method for recurrent uterine cervical cancer which can be performed safely.

• Authors: T Yokoyama, M Hiura, H Kaneko, M Yorishima, M Tanaka, T Chiba
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 15 Issue 1 Pg. 73-8 (Jan 1988) ISSN: 0385-0684 [Print] Japan
• PMID: 2447837 (Publication Type: English Abstract, Journal Article)

Chemical References

• Mitomycins
• Bleomycin
• Mitomycin
• Peplomycin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bleomycin (administration & dosage)
• Female
• Humans
• Infusions, Intravenous
• Injections, Intravenous
• Middle Aged
• Mitomycin
• Mitomycins (administration & dosage)
• Neoplasm Recurrence, Local (drug therapy, mortality)
• Peplomycin
• Uterine Cervical Neoplasms (drug therapy, mortality)